Trial · NCT05103332
Adverse events924
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 924
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site reaction | General disorders | Run-in: Indapamide | 0 | 127 | |
| other | Injection site reaction | General disorders | Run-in: Amlodipine | 0 | 238 | |
| other | Injection site reaction | General disorders | Run-in: Olmesartan | 0 | 293 | |
| other | Injection site reaction | General disorders | DB Period: Placebo (Add-on to Indapamide) | 0 | 64 | |
| other | Injection site reaction | General disorders | DB Period: Zilebesiran (Add-on to Indapamide) | 4 | 63 | |
| other | Injection site reaction | General disorders | DB Period: Placebo (Add-on to Amlodipine) | 0 | 120 | |
| other | Injection site reaction | General disorders | DB Period: Zilebesiran (Add-on to Amlodipine) | 2 | 118 | |
| other | Injection site reaction | General disorders | DB Period: Placebo (Add-on to Olmesartan) | 1 | 145 | |
| other | Injection site reaction | General disorders | DB Period: Zilebesiran (Add-on to Olmesartan) | 4 | 148 | |
| other | Injection site reaction | General disorders | DB Period (Placebo) to OLE Period (Zilebesiran) [Indapamide Cohort] | 0 | 26 | |
| other | Injection site reaction | General disorders | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Indapamide Cohort] | 5 | 63 | |
| other | Injection site reaction | General disorders | DB Period (Placebo) to OLE Period (Zilebesiran) [Amlodipine Cohort] | 0 | 48 | |
| other | Injection site reaction | General disorders | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Amlodipine Cohort] | 3 | 118 | |
| other | Injection site reaction | General disorders | DB Period (Placebo) to OLE Period (Zilebesiran) [Olmesartan Cohort] | 3 | 66 | |
| other | Injection site reaction | General disorders | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Olmesartan Cohort] | 7 | 148 | |
| other | Injection site reaction | General disorders | DB (Placebo) to SFU [Indapamide Cohort] | 0 | 38 | |
| other | Injection site reaction | General disorders | DB (Zilebesiran) to SFU or OLE to SFU [Indapamide Cohort] | 0 | 89 | |
| other | Injection site reaction | General disorders | DB (Placebo) to SFU [Amlodipine Cohort] | 0 | 72 | |
| other | Injection site reaction | General disorders | DB (Zilebesiran) to SFU or OLE to SFU [Amlodipine Cohort] | 0 | 166 | |
| other | Injection site reaction | General disorders | DB (Placebo) to SFU [Olmesartan Cohort] | 0 | 79 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05103332/events